BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31138104)

  • 21. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
    Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
    ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
    Dennis A; Wang L; Wan X; Ficker E
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1060-3. PubMed ID: 17956279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity.
    Koulgi S; Jani V; Nair V; Saini JS; Phukan S; Sonavane U; Joshi R; Kamboj R; Palle V
    J Biomol Struct Dyn; 2022 Aug; 40(13):5996-6012. PubMed ID: 33494645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BayeshERG: a robust, reliable and interpretable deep learning model for predicting hERG channel blockers.
    Kim H; Park M; Lee I; Nam H
    Brief Bioinform; 2022 Jul; 23(4):. PubMed ID: 35709752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.
    Wang S; Li Y; Wang J; Chen L; Zhang L; Yu H; Hou T
    Mol Pharm; 2012 Apr; 9(4):996-1010. PubMed ID: 22380484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Safe Drugs: The hERG Challenge.
    Kalyaanamoorthy S; Barakat KH
    Med Res Rev; 2018 Mar; 38(2):525-555. PubMed ID: 28467598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. hERG agonists pose challenges to web-based machine learning methods for prediction of drug-hERG channel interaction.
    El Harchi A; Hancox JC
    J Pharmacol Toxicol Methods; 2023; 123():107293. PubMed ID: 37468081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico prediction of hERG blockers using machine learning and deep learning approaches.
    Chen Y; Yu X; Li W; Tang Y; Liu G
    J Appl Toxicol; 2023 Oct; 43(10):1462-1475. PubMed ID: 37093028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.
    Kawai Y; Tsukamoto S; Ito J; Akimoto K; Takahashi M
    Chem Pharm Bull (Tokyo); 2011; 59(9):1110-6. PubMed ID: 21881254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and evaluation of an in silico model for hERG binding.
    Song M; Clark M
    J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea-pigs.
    Fabris F; Yue Y; Qu Y; Chahine M; Sobie E; Lee P; Wieczorek R; Jiang XC; Capecchi PL; Laghi-Pasini F; Lazzerini PE; Boutjdir M
    J Physiol; 2016 Nov; 594(21):6175-6187. PubMed ID: 27296897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.
    Liu LL; Lu J; Lu Y; Zheng MY; Luo XM; Zhu WL; Jiang HL; Chen KX
    Acta Pharmacol Sin; 2014 Aug; 35(8):1093-102. PubMed ID: 24976154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of the human ether-a-go-go-related gene (hERG) potassium channel by Nedd4 family interacting proteins (Ndfips).
    Kang Y; Guo J; Yang T; Li W; Zhang S
    Biochem J; 2015 Nov; 472(1):71-82. PubMed ID: 26363003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.